Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Shares Bought by Bain Capital Life Sciences Investors LLC

Bain Capital Life Sciences Investors LLC raised its position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 29.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,749,808 shares of the company’s stock after acquiring an additional 625,114 shares during the period. Syros Pharmaceuticals makes up 2.1% of Bain Capital Life Sciences Investors LLC’s investment portfolio, making the stock its 12th largest holding. Bain Capital Life Sciences Investors LLC owned 13.05% of Syros Pharmaceuticals worth $21,421,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. grew its holdings in shares of Syros Pharmaceuticals by 142.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 25,130 shares of the company’s stock worth $99,000 after acquiring an additional 14,754 shares during the period. CHI Advisors LLC increased its position in shares of Syros Pharmaceuticals by 69.3% in the third quarter. CHI Advisors LLC now owns 1,299,359 shares of the company’s stock valued at $5,119,000 after buying an additional 531,914 shares in the last quarter. Finally, Avidity Partners Management LP raised its stake in shares of Syros Pharmaceuticals by 8.0% during the 3rd quarter. Avidity Partners Management LP now owns 1,581,142 shares of the company’s stock worth $6,246,000 after buying an additional 117,108 shares during the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Trading Down 2.8 %

SYRS traded down $0.15 on Friday, reaching $5.15. 74,094 shares of the company’s stock were exchanged, compared to its average volume of 185,851. The company has a market cap of $137.65 million, a price-to-earnings ratio of -0.99 and a beta of 1.70. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.01 and a current ratio of 3.01. Syros Pharmaceuticals, Inc. has a twelve month low of $2.09 and a twelve month high of $8.17. The company’s 50 day moving average is $5.17 and its 200-day moving average is $5.80.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 395.36%. During the same period last year, the company earned ($0.85) earnings per share. Equities analysts predict that Syros Pharmaceuticals, Inc. will post -3.19 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $13.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd. StockNews.com upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, May 15th.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.